Registration of securities issued in business combination transactions

Patent Assignment and Royalty Agreement (Supera Pharmaceuticals, Inc.)

v3.20.4
Patent Assignment and Royalty Agreement (Supera Pharmaceuticals, Inc.)
12 Months Ended
Dec. 31, 2020
Supera Pharmaceuticals, Inc. [Member]  
Patent Assignment and Royalty Agreement

Note 5—Patent assignment and royalty agreement

 

In November 2020, the Company entered into an agreement with the holders of certain intellectual property relating to the Company’s current product candidate. Under the terms of the agreement, the counterparty assigned its rights and interest in certain patents to the Company in exchange for future royalty payments based on a fixed percentage of future revenues, as defined. The agreement is effective until the later of (1) the date of expiration of the assigned patents or (2) the date of expiration of the last strategic partnership or licensing agreement including the assigned patents.